Drug Approval | October 07, 2023
Lupin receives tentative approval from USFDA for Tolvaptan Tablets
Tolvaptan Tablets (RLD Jynarque) had estimated annual sales of USD 287 million in the U.S. (IQVIA MAT August 2023)
Tolvaptan Tablets (RLD Jynarque) had estimated annual sales of USD 287 million in the U.S. (IQVIA MAT August 2023)
Prior to this, Jim held leadership positions at several companies, including Centrient Pharmaceuticals, Leo Pharmaceuticals, Sandoz, Xellia, and GSK
Norepinephrine Bitartrate Injection is used for restoration of blood pressure in adult patients
Bains has stepped down from his role on the Biocon Board as an Independent Director with immediate effect
Norelgestromin and Ethinyl Estradiol Transdermal System, 150 mcg/35 mcg per day had annual sales of US $330 million in the United States
Low-leveraged balance sheets, sizeable liquidity to keep credit profiles stable
The products will be manufactured at the company's facility in Bengaluru
Strides Pharma Science Limited to acquire 100% in Strides Pharma Services Pvt Ltd.
This collaboration marks a significant milestone in countering the disease burden by enhancing access to products for patients in the US
This is a strategic acquisition for Cipla South Africa to unlock the future growth opportunities in the South African market
Subscribe To Our Newsletter & Stay Updated
